Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $145 from $135 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q3 sales beating consensus, driven by iDose and OUS MIGS. Management raised sales guidance by $5M at the midpoint, or the magnitude of the beat. Wells sees good momentum for iDose into Q4 and 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio